CPhI Worldwide, organized by UBM EMEA, announces the opening of the 2017 CPhI Pharma Awards.
Now in its 14th consecutive year, the awards have expanded to 20 categories* – accommodating the increased demand from companies across the full spectrum of pharma – with eight new additions reflecting the increased diversity of attendees at CPhI Worldwide.
The CPhI Pharma Awards, acknowledged as the most prestigious in the industry, will honor companies and individuals driving the pharma industry forward through innovations, technologies, and strategies. Last year, the awards received a record number of submissions with over 100 entries and CPhI Worldwide is expecting even greater interest in 2017.
In light of the increasingly dynamic pharma industry, new categories have been added to better mirror the market. For example, last year’s ‘Formulation and Excipients’ award is now split into two separate excellence awards, and two new categories have been created to evaluate company performance by size: ‘Pharma Company of the Year- Large’ and ‘Pharma Company of the Year- SME’.
Additionally, as the pharma industry places increased importance on sustainability, with a growing use of new practices, such as green chemistry and sustainable manufacturing, the ‘Sustainability Initiative of the Year’ award has been introduced.
A major part of CPhI Worldwide is helping its customers to expand into new markets and, this year, recognition is given to companies that have expanded internationally with the ‘Export Promotion’ award. Finally, three additional excellence awards have been created in order to reflect the growth of new audiences attending CPhI Worldwide: ‘OTC’, ‘Patent Centricity’, and ‘IT, mHealth, and Digitalization’.
Entries for the CPhI Pharma Awards are free of charge and the submission deadline is August 25th, 2017 – no entries submitted after this date will be valid for consideration – with shortlisted finalists announced September 1, 2017. The benefits of entering are recognition amongst industry peers and the senior judging panel, with the winners unveiled live at CPhI Worldwide during the CPhI Pharma Awards Gala Dinner (October 24, 2017). Finalists will also receive a unique profile of their award entry within the CPhI Show daily, and winners and finalists will be announced to the wider pharmaceutical industry media – giving these outstanding contributions the global profile they deserve.
To apply please visit http://awards.cphi.com/
* The full list of categories are:
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.